Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Erasca, Inc. faces a securities class action lawsuit after its stock plummeted 48% due to allegations of patent infringement by Revolution Medicines and the death of a patient treated with Erasca’s investigational drug ERAS-0015. The suit claims Erasca misled investors about the drug’s intellectual property protection…
Share This Article
Ready-to-post copy includes the article link.
Erasca Inc. Hit with Securities Class Action Following Patent Dispute and Patient Death, Market Value Drops $2.8 Billion Erasca, Inc. faces a securities class action lawsuit after its stock plummeted 48% due to allegations of patent infringement by Revolution Medicines and the death of a patient treated with Erasca’s investigational drug... Read the full IIPLA article: https://iipla.org/news/erasca-inc-hit-with-securities-class-action-following-patent-dispute-and-patient-death-market-value-drops-2-8-billion